Shots:
- Novartis has entered into an agreement to acquire Myricx Bio, strengthening Novartis’ oncology pipeline & advancing next-generation targeted drug conjugates with novel payload mechanisms
- Myricx is developing ADCs, using NMT inhibitor (NMTi) payloads designed to disrupt key cancer cell processes, with preclinical data showing broad activity across solid tumors, incl. TOPO-1-resistant models
- As per the deal, Novartis will acquire Myricx Bio for $1.1B upfront, with ~$400M in potential milestone payments; closing is expected in H2’26
Ref: Globenewswire | Image: Myricx Bio |Press Release
Related News: Antares Therapeutics Inks ~$1.9B Deal with Novartis for Undruggable Oncology Targets
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
